These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9372076)

  • 1. Preclinical studies and potential clinical applications of c-mpl ligand.
    Stead RB; Harker LA
    Curr Opin Hematol; 1996 May; 3(3):197-202. PubMed ID: 9372076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memorial lecture. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?
    Hofmann WK; Ottmann OG; Hoelzer D
    Leukemia; 1999 Apr; 13 Suppl 1():S14-8. PubMed ID: 10232362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo effects of Mpl ligand administration and emerging clinical applications for the Mpl ligands.
    Kuter DJ
    Curr Opin Hematol; 1997 May; 4(3):163-70. PubMed ID: 9209831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical use of thrombopoietin (c-Mpl Ligand)].
    Borota R; Borota J; Belić A; Gebauer E; Stefanović N
    Med Pregl; 1998; 51(11-12):501-8. PubMed ID: 10081270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action and clinical trials of Mpl ligand.
    Sheridan WP; Kuter DJ
    Curr Opin Hematol; 1997 Sep; 4(5):312-6. PubMed ID: 9288463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on thrombopoietin in preclinical and clinical trials.
    Miyazaki H
    Curr Opin Hematol; 1998 May; 5(3):197-202. PubMed ID: 9664160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?
    Hofmann WK; Ottmann OG; Hoelzer D
    Leukemia; 1999 Jan; 13(1):14-8. PubMed ID: 10049050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The structure, biology and potential therapeutic applications of recombinant thrombopoietin.
    Lok S; Foster DC
    Stem Cells; 1994 Nov; 12(6):586-98. PubMed ID: 7881359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells.
    Drexler HG; Quentmeier H
    Leukemia; 1996 Sep; 10(9):1405-21. PubMed ID: 8751457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic potential of thrombopoietin].
    Geissler K
    Wien Klin Wochenschr; 2000 Oct; 112(19):829-34. PubMed ID: 11098533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mpl ligand prevents lethal myelosuppression by inhibiting p53-dependent apoptosis.
    Pestina TI; Cleveland JL; Yang C; Zambetti GP; Jackson CW
    Blood; 2001 Oct; 98(7):2084-90. PubMed ID: 11567994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mpl ligand (thrombopoietin) and platelet regulation].
    Wendling F; Cohen-Solal K; Debili N; Villeval JL; Titeux M; Vainchenker W
    Ann Pharm Fr; 1996; 54(4):177-82. PubMed ID: 8881104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The physiologic role and therapeutic potential of the Mpl-ligand in thrombopoiesis.
    Hunt P
    Stem Cells; 1995 Nov; 13(6):579-87. PubMed ID: 8590859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
    Akahori H; Shibuya K; Ozai M; Ida M; Kabaya K; Kato T; Miyazaki H
    Stem Cells; 1996 Nov; 14(6):678-89. PubMed ID: 8948025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombopoietin (Mpl ligand) and the regulation of platelet production.
    Cohen-Solal K; Debili N; Vainchenker W; Wendling F
    Eur Cytokine Netw; 1997 Sep; 8(3):311-4. PubMed ID: 9346371
    [No Abstract]   [Full Text] [Related]  

  • 16. Thrombopoietin: biology and clinical potentials.
    Miyazaki H; Kato T
    Int J Hematol; 1999 Dec; 70(4):216-25. PubMed ID: 10643146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biology of thrombopoietin and its receptors].
    Robak T
    Postepy Hig Med Dosw; 1996; 50(6):649-63. PubMed ID: 9064684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoietin in vitro and in vivo.
    Alexander WS; Begley CG
    Cytokines Cell Mol Ther; 1998 Mar; 4(1):25-34. PubMed ID: 9557214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Mpl ligands on platelet production and function in nonhuman primates.
    Harker LA; Marzec UM; Kelly AB
    Stem Cells; 1998; 16 Suppl 2():107-19. PubMed ID: 11012183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A schedule of recombinant Mpl ligand highly effective at preventing lethal myelosuppression in mice given carboplatin and radiation.
    Abushullaih BA; Pestina TI; Srivastava DK; Jackson CW; Daw NC
    Exp Hematol; 2001 Dec; 29(12):1425-31. PubMed ID: 11750101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.